Session

Breakthroughs in IBD treatment and outcomes: Late-breaking abstracts

THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)
THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)

Breakthroughs in IBD treatment and outcomes: Late-breaking abstracts  et al.

INFLAMMATORY BOWEL DISEASE: A PHENOME-WIDE PRE- AND POST-DIAGNOSTIC ASSOCIATION STUDY
INFLAMMATORY BOWEL DISEASE: A PHENOME-WIDE PRE- AND POST-DIAGNOSTIC ASSOCIATION STUDY

Breakthroughs in IBD treatment and outcomes: Late-breaking abstracts  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Breakthroughs in IBD treatment and outcomes: Late-breaking abstracts  et al.

A RETROSPECTIVE COHORT STUDY TO COMPARE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
A RETROSPECTIVE COHORT STUDY TO COMPARE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Breakthroughs in IBD treatment and outcomes: Late-breaking abstracts  et al.

THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS
THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS

Breakthroughs in IBD treatment and outcomes: Late-breaking abstracts  et al.

THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)
THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)

INFLAMMATORY BOWEL DISEASE: A PHENOME-WIDE PRE- AND POST-DIAGNOSTIC ASSOCIATION STUDY
INFLAMMATORY BOWEL DISEASE: A PHENOME-WIDE PRE- AND POST-DIAGNOSTIC ASSOCIATION STUDY

THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS
THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS

A RETROSPECTIVE COHORT STUDY TO COMPARE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
A RETROSPECTIVE COHORT STUDY TO COMPARE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Item 1 - 10 / 10
1